Elsevier

Seminars in Oncology

Volume 28, Issue 4, August 2001, Pages 400-418
Seminars in Oncology

Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience

https://doi.org/10.1016/S0093-7754(01)90133-2Get rights and content

Abstract

The National Surgical Adjuvant Breast and Bowel Project (NSABP) conducted two sequential randomized clinical trials to aid in resolving uncertainty about the treatment of women with small, localized, mammographically detected ductal carcinoma in situ (DCIS). After removal of the tumor and normal breast tissue so that specimen margins were histologically tumor-free (lumpectomy), 818 patients in the B-17 trial were randomly assigned to receive either radiation therapy to the ipsilateral breast or no radiation therapy. B-24, the second study, which involved 1,804 women, tested the hypothesis that, in DCIS patients with or without positive tumor specimen margins, lumpectomy, radiation, and tamoxifen (TAM) would be more effective than lumpectomy, radiation, and placebo in preventing invasive and noninvasive ipsilateral breast tumor recurrences (IBTRs), contralateral breast tumors (CBTs), and tumors at metastatic sites. The findings in this report continue to demonstrate through 12 years of follow-up that radiation after lumpectomy reduces the incidence rate of all IBTRs by 58%. They also demonstrate that the administration of TAM after lumpectomy and radiation therapy results in a significant decrease in the rate of all breast cancer events, particularly in invasive cancer. The findings from the B-17 and B-24 studies are related to those from the NSABP prevention (P-l) trial, which demonstrated a 50% reduction in the risk of invasive cancer in women with a history of atypical ductal hyperplasia (ADH) or lobular carcinoma in situ (LCIS) and a reduction in the incidence of both DCIS and LCIS in women without a history of those tumors. The B-17 findings demonstrated that patients treated with lumpectomy alone were at greater risk for invasive cancer than were women in P-l who had a history of ADH or LCIS and who received no radiation therapy or TAM. Although women who received radiation benefited from that therapy, they remained at higher risk for invasive cancer than women in P-I who had a history of LCIS and who received placebo or TAM. Thus, if it is accepted from the P-I findings that women at increased risk for invasive cancer are candidates for an intervention such as TAM, then it would seem that women with a history of DCIS should also be considered for such therapy in addition to radiation therapy. That statement does not imply that, as a result of the findings presented here, all DCIS patients should receive radiation and TAM. It does suggest, however, that, in the treatment of DCIS, the appropriate use of current and better therapeutic agents that become available could diminish the significance of breast cancer as a public health problem.

References (50)

  • MD Lagios et al.

    Duct carcinoma in situ

    Cancer

    (1982)
  • B Fisher et al.

    Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer

    N Engl J Med

    (1985)
  • B Fisher et al.

    Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer

    N Engl J Med

    (1993)
  • B Fisher et al.

    Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel project B-17

    J Clin Oncol

    (1998)
  • ER Fisher et al.

    Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-17: Intraductal carcinoma (duct carcinoma in situ)

    Cancer

    (1995)
  • B Fisher et al.

    Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

    J Natl Cancer Inst

    (1996)
  • Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh

    Lancet

    (1987)
  • B Fisher et al.

    A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptorpositive tumors

    N Engl J Med

    (1989)
  • Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer

    Br J Cancer

    (1988)
  • LE Rutqvist et al.

    Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy

    J Natl Cancer Inst

    (1991)
  • B Fisher et al.

    New perspective on cancer of the contralateral breast: A marker for assessing tamoxifen as a preventive agent

    J Natl Cancer Inst

    (1991)
  • B Fisher et al.

    Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study

    J Natl Cancer Inst

    (1998)
  • B Fisher et al.

    Lumpectomy and axillary dissection for breast cancer: Surgical, pathological, and radiation considerations

    World J Surg

    (1985)
  • EL Kaplan et al.

    Nonparametric estimation from incomplete observations

    J Am Stat Assoc

    (1958)
  • N Mantel

    Evaluation of survival data and two new rank order statistics arising in its consideration

    Cancer Chemother Rep

    (1966)
  • Cited by (477)

    View all citing articles on Scopus

    Supported by Public Health Service Grants No. U10-CA-12027, U10-CA-69651, U10-CA-37377, and U10-CA-69974 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

    View full text